Market capitalization | $32.84b |
Enterprise Value | $45.48b |
P/E (TTM) P/E ratio | 24.88 |
EV/FCF (TTM) EV/FCF | 21.51 |
EV/Sales (TTM) EV/Sales | 2.95 |
P/S ratio (TTM) P/S ratio | 2.13 |
P/B ratio (TTM) P/B ratio | 5.41 |
Revenue growth (TTM) Revenue growth | 2.95% |
Revenue (TTM) Revenue | $15.41b |
As a Free StocksGuide user, you can view scores for all 6,809 stocks worldwide.
27 Analysts have issued a IQVIA forecast:
27 Analysts have issued a IQVIA forecast:
Dec '24 |
+/-
%
|
||
Revenue | 15,405 15,405 |
3%
3%
|
|
Gross Profit | 4,261 4,261 |
4%
4%
|
|
EBITDA | 3,383 3,383 |
7%
7%
|
EBIT (Operating Income) EBIT | 2,269 2,269 |
11%
11%
|
Net Profit | 1,373 1,373 |
1%
1%
|
In millions USD.
If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.
Provides biopharmaceutical development services and commercial outsourcing services
Head office | United States |
CEO | Ari Bousbib |
Employees | 88,000 |
Founded | 1950 |
Website | www.iqvia.com |
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.